Full Text Journal Articles in
Journal Eur Urol Oncol

Advertisement

Find full text journal articles






Re: Andrew Erickson, Alicia Hayes, Timothy Rajakumar, et al. A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease. Eur Urol Oncol 2021;4:358-69.

Jeroen Kneppers, Hilda de Barros, Henk van der Poel,

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights.

Daniel Benamran, Laurence Albiges, Axel Bex, Gianluca Giannarini, Umberto Capitanio, Morgan Rouprêt, ,

This clinical case-based discussion focuses on a 73-yr-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with systemic therapy. Current guideline-based treatment options are presented and critically examined. The discussion covers the main aspects of the management of metastatic RCC, such as the role of cytoreductive ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.

Armando Stabile, Antony Pellegrino, Elio Mazzone, Donato Cannoletta, Mario de Angelis, Francesco Barletta, Simone Scuderi, Vito Cucchiara, Giorgio Gandaglia, Daniele Raggi, Andrea Necchi, Pierre Karakiewicz, Francesco Montorsi, Alberto Briganti,

<h4>Context</h4>The role of positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA) in the primary staging for patients with prostate cancer (PCa) is still debated.<h4>Objective</h4>To analyze published studies reporting the accuracy of PSMA PET/CT for detecting lymph node invasion (LNI) at pelvic lymph node dissection (PLND).<h4>Evidence acquisition</h4>A search of ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Re: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(21)00152-2: The Conflict of Adding Immunotherapy to Chemotherapy in Metastatic Urothelial Carcinoma: A Matter of the Right Timing?

Veronica Mollica, Alessandro Rizzo, Francesco Massari,

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Re: Karim A. Touijer, Daniel D. Sjoberg, Nicole Benfante, et al. Limited Versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2021.03.006.

Bin Yang, Guanjie Yang, Xudong Yao,

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Equity in Drug Accessibility: The Surprising Case of Treatments for Metastatic Castration-sensitive Prostate Cancer in European Countries.

Orazio Caffo, Massimo Di Maio,

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature.

Adam K Aragaki, Yuezhou Jing, Jean Hoffman-Censits, Woonyoung Choi, Noah M Hahn, Bruce J Trock, David J McConkey, Burles A Johnson,

<h4>Background</h4>There is a great need to identify biomarkers that can accurately identify patients who will obtain the most clinical benefit from immune checkpoint inhibitor (ICI) therapy. While high intratumoral B cell gene expression correlated with an ICI response in melanoma, whether it adds predictive value in other cancers is unknown.<h4>Objective</h4>To ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.

Brandon A Mahal, Travis Gerke, Shivanshu Awasthi, Howard R Soule, Jonathan W Simons, Andrea Miyahira, Susan Halabi, Daniel George, Elizabeth A Platz, Lorelei Mucci, Kosj Yamoah,

<h4>Context</h4>Prostate cancer (PCa) is a complex disease that disproportionately impacts Black men in the USA. The structural factors that drive heterogeneous outcomes for patients of differing backgrounds are probably the same ones that result in population-level disparities. The relative contribution of drivers along the PCa disease continuum is an active ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).

John N Staffurth, Joanne S Haviland, Anna Wilkins, Isabel Syndikus, Vincent Khoo, David Bloomfield, Chris Parker, John Logue, Christopher Scrase, Alison Birtle, Zafar Malik, Miguel Panades, Chinnamani Eswar, John Graham, Martin Russell, Catherine Ferguson, Joe M O'Sullivan, Clare A Cruickshank, David Dearnaley, Emma Hall, ,

<h4>Background</h4>Moderate hypofractionation is the recommended standard of care for localised prostate cancer following the results of trials including Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer (CHHiP). Evaluation of long-term patient-reported outcomes (PROs) is important to confirm safety and enhance patient information.<h4>Objective</h4>To determine whether 5-yr PROs from ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer.

Hendrik Van Poppel, Renée Hogenhout, Peter Albers, Roderick C N van den Bergh, Jelle O Barentsz, Monique J Roobol,

<h4>Context</h4>Overdiagnosis as the argument to stop prostate cancer (PCa) screening is less valid since the introduction of new technologies such as risk calculators (RCs) and magnetic resonance imaging (MRI). These new technologies result in fewer unnecessary biopsy procedures and fewer cases of both overdiagnosis and underdetection. Therefore, we can now ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer.

Tessel E Galesloot, Anne J Grotenhuis, Dimitar Kolev, Katja K Aben, Richard T Bryan, James W F Catto, Kar K Cheng, Samantha Conroy, Lars Dyrskjøt, Neil E Fleshner, Nicholas D James, Philippe Lamy, Sia Viborg Lindskrog, Núria Malats, Lourdes Mengual, Gerald Verhaegh, Maurice P Zeegers, Lambertus A L M Kiemeney, Sita H Vermeulen,

<h4>Background</h4>Non-muscle-invasive bladder cancer (NMIBC) is characterized by frequent recurrences and a risk of progression in stage and grade. Increased knowledge of underlying biological mechanisms is needed.<h4>Objective</h4>To identify single nucleotide polymorphisms (SNPs) associated with recurrence-free (RFS) and progression-free (PFS) survival in NMIBC.<h4>Design, setting, and participants</h4>We analyzed outcome data from 3400 newly ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Reply to Anwar R. Padhani, Ivo G. Schoots, Jelle O. Barentsz. Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2021.04.009: Fast-MRI Feasibility in Biopsy-naïve Patients: Clarifications on the Study Methods and Results.

Filippo Russo, Simone Mazzetti, Daniele Regge, Ilaria Ambrosini, Valentina Giannini, Matteo Manfredi, Stefano De Luca, Enrico Bollito, Francesco Porpiglia,

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Intermediate-risk Prostate Cancer-A Sheep in Wolf's Clothing?

Isabel Heidegger, Freddie C Hamdy, Roderick C N van den Bergh, Axel Heidenreich, Michiel Sedelaar, Morgan Roupret, ,

This case-based discussion describes a 65-year-old man newly diagnosed with International Society of Urological Pathology (ISUP) grade 2 prostate cancer (PCa). According to the European Association of Urology classification system, the patient harbors an intermediate-risk cancer. In step-by step discussion, we elaborate guideline-based treatment modalities for intermediate-risk PCa focused on ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.

Reza Sari Motlagh, Mohammad Abufaraj, Keiichiro Mori, Abdulmajeed Aydh, Pawel Rajwa, Satoshi Katayama, Nico C Grossmann, Ekaterina Laukhtina, Hadi Mostafai, Benjamin Pradere, Fahad Quhal, Pierre I Karakiewicz, Dmitry V Enikeev, Shahrokh F Shariat,

<h4>Context</h4>Degarelix is associated with high rates of injection site reaction. The US Food and Drug Administration approved relugolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of advanced prostate cancer patients.<h4>Objective</h4>This systematic review and network meta-analysis aimed to compare the efficacy and safety of relugolix versus degarelix.<h4>Evidence acquisition</h4>A systematic ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.

Brian I Rini, Michael B Atkins, Elizabeth R Plimack, Denis Soulières, Raymond S McDermott, Jens Bedke, Sophie Tartas, Boris Alekseev, Bohuslav Melichar, Yaroslav Shparyk, Chihiro Kondoh, Przemyslaw Langiewicz, Lori A Wood, Hans Hammers, Cynthia G Silber, Barbara Haber, Erin Jensen, Mei Chen, Thomas Powles,

<h4>Background</h4>Pembrolizumab plus axitinib improved efficacy over sunitinib in treatment-naive advanced renal cell carcinoma in the KEYNOTE-426 (NCT02853331) study. However, a relatively high incidence of grade 3/4 aminotransferase elevations was observed.<h4>Objective</h4>To further characterize treatment-emergent aminotransferase elevations in patients treated with pembrolizumab-axitinib.<h4>Design, setting, and participants</h4>Patients enrolled in KEYNOTE-426 were included in this ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Bründl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol 2021;4:182-91: Image Analysis, Nuclear Abnormality Index, and Pattern Recognition Analysis.

Alessia Cimadamore, Antonio Lopez-Beltran, Marina Scarpelli, Liang Cheng, Rodolfo Montironi,

Eur Urol Oncol (European urology oncology)
[2021, 4(4):671-673]

Cited: 0 times

View full text PDF listing >>



Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.

Carlo A Bravi, Matteo Droghetti, Nicola Fossati, Giorgio Gandaglia, Nazareno Suardi, Elio Mazzone, Vito Cucchiara, Simone Scuderi, Francesco Barletta, Riccardo Schiavina, Daniar Osmonov, Klaus-Peter Juenemann, Luca Boeri, R Jeffrey Karnes, Alexander Kretschmer, Alexander Buchner, Christian Stief, Andreas Hiester, Alessandro Nini, Peter Albers, Gaëtan Devos, Steven Joniau, Hendrik Van Poppel, Bernhard Grubmüller, Shahrokh F Shariat, Axel Heidenreich, David Pfister, Derya Tilki, Markus Graefen, Inderbir S Gill, Alexandre Mottrie, Pierre I Karakiewicz, Francesco Montorsi, Alberto Briganti,

<h4>Background</h4>The optimal definition and prognostic significance of persistently elevated prostate-specific antigen (PSA) after salvage lymph node dissection (sLND) for node-only recurrent prostate cancer (PCa) remain unknown.<h4>Objective</h4>To assess the definition and clinical implications of persistently elevated PSA after sLND for node-only recurrent PCa after radical prostatectomy.<h4>Design, setting, and participants</h4>The study included ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Managing Discordant Findings Between Multiparametric Magnetic Resonance Imaging and Transrectal Magnetic Resonance Imaging-directed Prostate Biopsy-The Key Role of Magnetic Resonance Imaging-directed Transperineal Biopsy.

Anne-Sophie Bajeot, Bertrand Covin, Oliver Meyrignac, Sarah Pericart, Richard Aziza, Daniel Portalez, Pierre Graff-Cailleaud, Guillaume Ploussard, Mathieu Roumiguié, Bernard Malavaud,

<h4>Background</h4>Discordant findings between multiparametric magnetic resonance imaging (mpMRI) and transrectal image-guided biopsies of the prostate (TRUS-P) may result in inadequate risk stratification of localized prostate cancer.<h4>Objective</h4>To assess transperineal image-guided biopsies of the index target (TPER-IT) in terms of disease reclassification and treatment recommendations.<h4>Design, setting, and participants</h4>Cases referred for suspicion or ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 1 time

View full text PDF listing >>



Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations.

Nicolas Sayegh, Neeraj Agarwal, Umang Swami,

Eur Urol Oncol (European urology oncology)
[2021, 4(4):553-557]

Cited: 0 times

View full text PDF listing >>



Mortality Trends from Urologic Cancers in Europe over the Period 1980-2017 and a Projection to 2025.

Paola Bertuccio, Claudia Santucci, Greta Carioli, Matteo Malvezzi, Carlo La Vecchia, Eva Negri,

<h4>Background</h4>Patterns and trends in urologic cancer mortality still show geographical differences across Europe.<h4>Objective</h4>To monitor mortality trends from urologic cancers, including prostate, testis, bladder, and kidney cancers, in Europe.<h4>Design, setting, and participants</h4>We carried out a time-trend analysis for 36 European countries using the official World Health Organization database.<h4>Outcome measurements and statistical ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.

Alice Boilève, Pernelle Lavaud, Olivier Caron,

Eur Urol Oncol (European urology oncology)
[2021, 4(4):674-675]

Cited: 0 times

View full text PDF listing >>



Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer.

Gianluca Giannarini, Neeraj Agarwal, Andrea B Apolo, Alberto Briganti, Petros Grivas, Shilpa Gupta, Ashish M Kamat, Francesco Montorsi, Morgan Rouprêt, Andrea Necchi,

Novel immune checkpoint inhibitors hold promise for non-muscle-invasive bladder cancer. Cooperation between urologists and other multidisciplinary bladder cancer specialists can surmount the challenges involved in using these agents in bladder-sparing approaches. This strategy could deliver a new era of comprehensive evaluation and multimodal treatment for this patient population. ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma.

Michael A Gorin, Hiten D Patel, Steven P Rowe, Noah M Hahn, Hans J Hammers, Alice Pons, Bruce J Trock, Phillip M Pierorazio, Thomas R Nirschl, Daniela C Salles, Julie E Stein, Tamara L Lotan, Janis M Taube, Charles G Drake, Mohamad E Allaf,

Neoadjuvant immune checkpoint blockade represents a novel approach for potentially decreasing the risk of recurrence in patients with nonmetastatic renal cell carcinoma (RCC). In this early phase clincal tiral, we evaluated the safety and tolerability of neoadjuvant treatment with the programmed cell death protein 1 (PD-1) inhibitor nivolumab in patients ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Locally Advanced Kidney Cancer: A New Space for Immunotherapy?

Nirmish Singla, Vitaly Margulis,

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press: Incidental Prostate Cancer: An Example of How Important Guidelines Are, Especially When Evidence Is Limited.

Umberto Capitanio, Riccardo Autorino, Marco Bandini, Alberto Briganti, Liang Cheng, Matthew R Cooperberg, Federico Dehò, Andrea Gallina, Laurence Klotz, Brian R Lane, Rodolfo Montironi, Andrea Salonia, Christian Stief, Bertrand Tombal, Francesco Montorsi,

Eur Urol Oncol (European urology oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.1089 s